Deleted Tweets From Scott Gottlieb, R-D.C.
Scott Gottlieb's accounts: SteveFDA
Tracked Between: October 20, 2017-January 20, 2021
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDATobacco: Breathing tobacco smoke can damage the heart and blood vessels of nonsmokers, too. #HeartMonth… https://t.co/Ya7tAUGY1p
SteveFDA (R-D.C.)
@SGottliebFDA
Happy #ValentinesDay! Leave the pack for good so cigarette smoke isn’t clouding out the love in the air: https://t.co/OYqh9DhA3R #healthpolicyvalentines https://t.co/loVbisbJvz
SteveFDA (R-D.C.)
@SGottliebFDA
If you’re planning treats for your four-legged pal this #ValentinesDay, make sure they’re pet-appropriate. #NoChocolate https://t.co/2cILmXZ2eI https://t.co/gHwPkg8Y9N
SteveFDA (R-D.C.)
@SGottliebFDA
RT @NBCOlympics: SHAUN WHITE IS NOT HUMAN. #BestOfUS #WinterOlympics https://t.co/r5PfUbeROr https://t.co/6MmQiSZGRh
SteveFDA (R-D.C.)
@SGottliebFDA
ICYMI: The 2018 Adult Immunization Schedule #VaccinesWork https://t.co/Ij50INdoAr
SteveFDA (R-D.C.)
@SGottliebFDA
RT @Surgeon_General: Recovery is personal. Each person's recovery journey is unique. People will choose their pathway based on their c… https://t.co/tXUPUPL35s
SteveFDA (R-D.C.)
@SGottliebFDA
RT @US_FDA: Learn more about FDA actions and research related to traumatic brain injury/concussions: https://t.co/l2T1jzv5pp https://t.co/… QT @US_FDA: FDA authorizes marketing of 1st blood test to aid in eval of concussion in adults. Most patients eval'd for concuss… https://t.co/7jTV1xbsEu)
SteveFDA (R-D.C.)
@SGottliebFDA
RT @megtirrell: Fascinating -- FDA approves first blood test to evaluate concussion in adults; says it could rule out need for CT s… https://t.co/CfbLIpQG2t
SteveFDA (R-D.C.)
@SGottliebFDA
1/3 My remarks today about the ways FDA is getting ahead of new opioid threats and addressing those crises that are already fully manifest. https://t.co/9fizFfAnYD
SteveFDA (R-D.C.)
@SGottliebFDA
2/3Though it merits consideration through a careful, science-based process, one action that we’re examining is blister packaging of the immediate release formulations of opioid drugs. https://t.co/9fizFfAnYD
SteveFDA (R-D.C.)
@SGottliebFDA
3/3 FDA is investigating whether the abuse or misuse of gabapentinoids is increasing and, if so, what should be done to address the problem. https://t.co/9fizFfAnYD
SteveFDA (R-D.C.)
@SGottliebFDA
RT @annaedney: The FDA Commissioner with some opioid news. Agency is investigating whether people are abusing epilepsy drug gabapentin (Neu… QT @SGottliebFDA: 1/3 My remarks today about the ways FDA is getting ahead of new opioid threats and addressing those crises that are… https://t.co/pIiWVoCdbz)
SteveFDA (R-D.C.)
@SGottliebFDA
RT @CBSHealth: It's the first blood test approved for detecting brain injuries https://t.co/FTCFgcWoj8
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAMedia: Statement from @SGottliebFDA on the efficacy of the 2017-2018 influenza vaccine: https://t.co/cbveuYKulU
SteveFDA (R-D.C.)
@SGottliebFDA
SteveFDA (R-D.C.)
@SGottliebFDA
“Gottlieb also said that a national e-prescribing system for controlled substances... could help reduce prescription drug abuse and strengthen efforts to reduce the risk of certain prescription drugs.” via @RAPSorg https://t.co/uNXdhe4DfF
SteveFDA (R-D.C.)
@SGottliebFDA
1/5 Our new Alzheimer’s guidance lays groundwork for innovative approaches to studying early disease before the onset of dementia, including strategies for trials incorporating patients with very early Alzheimer’s who haven’t yet experienced any symptoms
SteveFDA (R-D.C.)
@SGottliebFDA
2/5 Our guidance reflects the understanding of the medical community that delaying or halting Alzheimer’s disease processes that lead to symptoms is the ultimate goal of treatment at this stage. https://t.co/FvgWOYDjeJ
SteveFDA (R-D.C.)
@SGottliebFDA
3/5 We recognize the important role that scientifically valid biomarkers can play in clinical studies of very early Alzheimer’s. Objective tests and diagnostic criteria are important to ensure proper enrollment.
SteveFDA (R-D.C.)
@SGottliebFDA
RT @CDCDirector: Early estimates show that #flu vaccine was 51% effective against H3N2, among children ages 6 months- 8 years of age… https://t.co/xLvVfMAAoc